Glypican-5 Polyclonal antibody

Glypican-5 Polyclonal Antibody for WB, ELISA
Cat No. 30999-1-AP

产品说明书

宿主/亚型

Rabbit / IgG

种属反应性

human

应用

WB, ELISA

GPC5, Secreted glypican-5, glypican 5

缓冲液配方:  PBS and Azide
PBS and Azide
偶联物:  Unconjugated
Unconjugated
规格: 

-/ -


经过测试的应用

Positive WB detected inHeLa cells, NCI-H1299 cells

推荐稀释比

应用推荐稀释比
Western Blot (WB)WB : 1:1000-1:6000
It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, Check data in validation data gallery.

产品信息

30999-1-AP targets Glypican-5 in WB, ELISA applications and shows reactivity with human samples.

经测试应用 WB, ELISA Application Description
经测试反应性 human
免疫原 Glypican-5 fusion protein Ag34039 种属同源性预测
宿主/亚型 Rabbit / IgG
抗体类别 Polyclonal
产品类型 Antibody
全称 glypican 5
别名 GPC5, Secreted glypican-5, glypican 5
计算分子量 572 aa, 64 kDa
观测分子量63 kDa
GenBank蛋白编号BC039730
基因名称 Glypican 5
Gene ID (NCBI) 2262
偶联类型 Unconjugated
形式 Liquid
纯化方式Antigen affinity Purification
UNIPROT IDP78333
储存缓冲液 PBS with 0.02% sodium azide and 50% glycerol , pH 7.3
储存条件Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.

背景介绍

Glypican-5 (GPC5), which is predicted to be located in the cell membrane. In adult, primarily expressed in the brain. Also detected in fetal brain, lung and liver (PMID: 9070915). Glypican-5 is a member of heparan sulfate proteoglycans. The repressive role of GPC5 intumorigenesis has been reported in a variety of cancers, including rhabdomyosarcoma, breast cancer, and prostate cancer. GPC5, which is lowly expressed in lung cancer tissues compared with adjacent noncancerous tissues, exhibits a suppressive effect on migration and invasion, and it can also induce G1/S phase arrest of the lung cancer cells in vitro, which is associated with a better prognosis (PMID: 34079082). The molecular weight of Glypican-5 is 63 kDa.

实验方案

Product Specific Protocols
WB protocol for Glypican-5 antibody 30999-1-APDownload protocol
Standard Protocols
Click here to view our Standard Protocols
Loading...